Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03KHQ
|
|||
| Former ID |
DIB003727
|
|||
| Drug Name |
DNA-Ad
|
|||
| Synonyms |
DNA-prime/adenovirus (Ad5)-boost CSP-and AMA1-encoding malaria vaccine (Biojector2000, intramuscular), US NavalMedical Research Center (NMRC)/Bioject/Vical/GenVec
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Malaria [ICD-11: 1F40-1F45; ICD-10: B50-B64, B54] | Phase 1/2 | [1] | |
| Company |
US Naval Medical Research Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Plasmodium Apical membrane protein (Malaria AMA-1) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00870987) Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria. U.S. National Institutes of Health. | |||
| REF 2 | Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One. 2014 Sep 11;9(9):e106241. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.